Assertio (ASRT) Projected to Post Quarterly Earnings on Monday

Assertio (NASDAQ:ASRT) is expected to be announcing its Q1 2026 results after the market closes on Monday, May 11th. Analysts expect the company to announce earnings of ($2.1025) per share and revenue of $8.9660 million for the quarter. Individuals can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Friday, May 8, 2026 at 4:00 PM ET.

Assertio (NASDAQ:ASRT) last announced its earnings results on Monday, March 16th. The company reported ($1.86) EPS for the quarter, beating analysts’ consensus estimates of ($3.05) by $1.19. Assertio had a negative net margin of 25.59% and a negative return on equity of 30.26%. The business had revenue of $13.54 million during the quarter, compared to analysts’ expectations of $6.20 million. On average, analysts expect Assertio to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Assertio Stock Performance

Shares of NASDAQ:ASRT traded up $3.21 on Monday, reaching $21.68. The company’s stock had a trading volume of 1,759,771 shares, compared to its average volume of 141,076. The stock’s 50-day moving average is $15.65 and its two-hundred day moving average is $12.86. Assertio has a 52-week low of $8.61 and a 52-week high of $21.71. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.70 and a quick ratio of 1.51. The stock has a market capitalization of $139.84 million, a P/E ratio of -4.46 and a beta of 0.44.

Hedge Funds Weigh In On Assertio

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ASRT. Opaleye Management Inc. acquired a new position in shares of Assertio during the 4th quarter worth approximately $2,585,000. Nantahala Capital Management LLC raised its position in shares of Assertio by 4.4% during the 2nd quarter. Nantahala Capital Management LLC now owns 8,810,073 shares of the company’s stock worth $5,649,000 after purchasing an additional 370,311 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Assertio by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 4,425,543 shares of the company’s stock worth $3,899,000 after purchasing an additional 41,332 shares during the last quarter. Edgewood Management LLC acquired a new position in shares of Assertio during the 4th quarter worth approximately $975,000. Finally, Perritt Capital Management Inc raised its position in shares of Assertio by 51.6% during the 3rd quarter. Perritt Capital Management Inc now owns 350,316 shares of the company’s stock worth $309,000 after purchasing an additional 119,281 shares during the last quarter. Institutional investors and hedge funds own 48.96% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Maxim Group cut shares of Assertio from a “strong-buy” rating to a “hold” rating in a report on Thursday, April 9th. Lake Street Capital cut shares of Assertio from a “buy” rating to a “hold” rating and cut their price target for the stock from $45.00 to $18.00 in a report on Thursday, April 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Assertio in a report on Monday, April 20th. Zacks Research cut shares of Assertio from a “strong-buy” rating to a “hold” rating in a report on Friday, March 6th. Finally, HC Wainwright reissued a “neutral” rating and set a $18.00 price target (down from $35.00) on shares of Assertio in a report on Thursday, April 9th. One equities research analyst has rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Assertio has a consensus rating of “Hold” and a consensus price target of $18.00.

Assertio Company Profile

Assertio Therapeutics, Inc, formerly known as Depomed, is a specialty pharmaceutical company focused on the development and commercialization of therapies for central nervous system (CNS) disorders, including neuropathic pain, migraine and breakthrough cancer pain. The company’s commercial portfolio includes three FDA-approved products—Qutenza (8% capsaicin) for postherpetic neuralgia, Butrans (buprenorphine) transdermal system for chronic pain and Onsolis (fentanyl buccal soluble film) for breakthrough cancer pain—which are marketed primarily in the United States under licensing agreements with global partners.

In addition to its marketed therapies, Assertio maintains a pipeline of preclinical and clinical-stage candidates targeting a range of pain and neurological conditions.